Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
NCT ID: NCT00689208
Last Updated: 2009-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
12 participants
INTERVENTIONAL
2007-05-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease
NCT06912048
Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients
NCT00953914
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
NCT02025608
Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake
NCT03800290
Neostigmine Reversal And Neuromuscular Recovery
NCT02433808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atropine
10 ug/kg bolus, 4 ug/kg/h infusion
Physostigmine
0,12ug/kg/min
Placebo Sodium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of lean and abdominally obese men and women
* weight stable
Exclusion Criteria
* History of repeated syncope
* resting pulse\<50 or systolic blood pressure \<100
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca R&D Mölndal, Sweden
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Per-Anders Jansson, prof
Role: PRINCIPAL_INVESTIGATOR
Lundberg Laboratory for diabetic research, Sahlgrenska Universitetssjukhuset Göteborg, Sweden
Jan Eriksson, MSD
Role: STUDY_CHAIR
Clinical Cardiovascular gastrointestinal departmentAstraZeneca R&D Mölnda Swedenl
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D4411M00007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.